Maze Therapeutics, Inc.

MAZE Nasdaq CIK: 0001842295

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
Mailing Address 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
Phone 6508505070
Fiscal Year End 1231
EIN 000000000

Recent SEC Filings

Form Type Date Filed Document
3 Initial insider ownership report March 31, 2026 View on SEC
4 Insider stock transaction report March 31, 2026 View on SEC
10-K Annual financial report March 25, 2026 View on SEC
8-K Current report of material events March 25, 2026 View on SEC
4 Insider stock transaction report March 20, 2026 View on SEC
4 Insider stock transaction report March 12, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC

Annual Reports

10-K March 25, 2026
  • Successfully completed IPO on the Nasdaq under ticker 'MAZE', raising $150 million.
  • Utilizes the proprietary 'Compass' platform to identify genetic variations for drug development.
View Analysis

Insider Trading

STRONG SELL 4 insiders 35 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.